Successful Treatment of a Miliary Metastatic NSCLC Patient With Activating EGFR Exon 20 Insertion Mutation with Response to Poziotinib

被引：6
作者：
Yang, Juyin [1 ]
Yang, Jian [2 ]
Ban, Shao [3 ]
Li, Xinmin [2 ]
Chen, Xingde [4 ]
Yang, Jihua [4 ]
Qian, Jun [2 ]
机构：
[1] Kunming Med Univ, Affiliated Dehong Peoples Hosp, Dept Pharm, Dehong, Yunnan, Peoples R China
[2] Kunming Med Univ, Affiliated Dehong Peoples Hosp, Dept Cardiothorac Surg, 13 Yonghan St, Dehong 678400, Yunnan, Peoples R China
[3] Kunming Med Univ, Affiliated Dehong Peoples Hosp, Dept Cardiovasc Med, Dehong, Yunnan, Peoples R China
[4] Kunming Med Univ, Affiliated Dehong Peoples Hosp, Dept Pathol, Dehong, Yunnan, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 09期
关键词：
D O I：
10.1016/j.jtho.2019.04.031
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E198 / E200
页数：3
相关论文
共 50 条
  • [31] Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report
    Chen, Xuesong
    Zha, Wangjian
    Su, Mei
    Meng, Nan
    Cao, Shuliang
    Niu, Beifang
    Qi, Xu
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [32] CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation
    Pan, Minggui
    Santamaria, Monica
    Wollman, David B.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2007, 4 (10): : 603 - 607
  • [33] Circulating tumor DNA (ctDNA) in HER2 exon 20 insertion mutations and responses in NSCLC HER2 exon 20 insertion treated with poziotinib
    不详
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [34] CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation
    Minggui Pan
    Monica Santamaria
    David B Wollman
    Nature Clinical Practice Oncology, 2007, 4 : 603 - 607
  • [35] ZENITH20, a multinational, multi-cohort phase II study of poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations
    Socinski, M. A.
    Cornelissen, R.
    Garassino, M. C.
    Clarke, J.
    Tchekmedyian, N.
    Molina, J.
    Goldman, J. W.
    Bhat, G.
    Lebel, F.
    Le, X.
    ANNALS OF ONCOLOGY, 2020, 31 : S1188 - S1188
  • [36] A rare EGFR exon 19 insertion mutation in metastatic lung adenocarcinoma: a favorable response to afatinib
    Seven, Ismet
    Kos, Fahriye Tugba
    Dogan, Hayriye Tatli
    Kislal, Mustafa Hayri
    Sekmek, Serhat
    Karahan, Irfan
    Esen, Selin Akturk
    Uncu, Dogan
    ANTI-CANCER DRUGS, 2025, 36 (02) : 151 - 153
  • [37] Real-world response and outcomes in NSCLC patients with EGFR exon 20 insertion mutations.
    Ou, Sai-Hong Ignatius
    Lin, Huamao Mark
    Hong, Jin-Liern
    Yin, Yu
    Jin, Shu
    Lin, Jianchang
    Mehta, Minal
    Nguyen, Danny
    Neal, Joel W.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] Patient with metastatic lung adenocarcinoma with the presence of an activating mutation in exon 21 of the EGFR gene treated with Erlotinib
    Kowalski, Dariusz M.
    ONCOLOGY IN CLINICAL PRACTICE, 2014, 10 : G10 - G10
  • [39] Paraneoplastic Hypomyopathic Dermatomyositis Associated With EGFR Exon-20 Insertion NSCLC
    Zhong, Connie S.
    Russell-Goldman, Eleanor
    Murphy, George F.
    Nambudiri, Vinod E.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (06) : E128 - E130
  • [40] Clinical outcomes of EGFR exon 20 insertion in advanced NSCLC in Korea.
    Byeon, Seonggyu
    Kim, Youjin
    Lee, Jiyun
    Sun, Jong-Mu
    Choi, Yoon-La
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345